The U.S. Food and Drug Administration (FDA) has cleared cardiovascular software developer HeartFlow's HeartFlow Planner, a real-time virtual modeling software application for coronary artery disease (CAD) intervention.
The software enables interventional cardiologists to model clinical scenarios, explore treatment strategies for patients with CAD before each procedure, and review cases with colleagues, the company said. It is based on the company's HeartFlow Analysis, a color-coded 3D model of a patient's coronary arteries.
HeartFlow plans to highlight HeartFlow Planner at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco.
